dietmar berger gilead news

Gilead appoints Dietmar Berger

Gilead appoints Sanofi official Dietmar Berger as next chief medical officer

Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who is preparing to leave early next year.Berger, who will join on Jan.

YAHOO!Finance · 1d

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead’s senior leadership team.

MarketWatch · 1d

Gilead Sciences Names Sanofi's Berger as Next Chief Medical Officer

Gilead Sciences named former Sanofi executive Dietmar Berger as chief medical officer, effective Jan. 2, succeeding Merdad Parsey.

Business Insider · 1d

Gilead appoints Dietmar Berger as Chief Medical Officer

Gilead (GILD) announced that Dietmar Berger will join the company on January 2, 2025, as Chief Medical Officer and will become a member of

BioPharma Dive5h

Dietmar Berger is Gilead’s new CMO; Padlock investors sue Bristol Myers

Gilead CEO Daniel O’Day has hired Berger away from Sanofi. Elsewhere, Lonza is reorganizing and Bausch + Lomb is exploring a ...

FierceBiotech14h

Gilead's Daniel O'Day relishes Dietmar Berger reunion as cancer specialist agrees to join from Sanofi

Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...

ENDPOINTS NEWS12h

Gilead names Dietmar Berger CMO as it eyes R&D reset

Gilead Sciences names Sanofi's Dietmar Berger as new CMO, replacing Merdad Parsey amid challenging year marked by setbacks ...

The Pharma Letter11h

Gilead Sciences names new CMO

US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...

pharmaphorum5y

Sanofi names ex-Roche cancer guru Dietmar Berger as development lead

Roche alumnus Dietmar Berger has joined Sanofi as head of development ... with cell therapies from Kite/Gilead under a deal announced in 2016 – eventually led Berger to be tempted away to ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results